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mDr Cartier150 The Journal of Thoracic and Cardbjectives: Aortic stenosis is one of the most common forms of acquired valvular
eart disease in adults, and the proportion of patients unsuitable for conventional
urgery is increasing. Consequently, the development of new less-invasive tech-
iques to treat severe aortic stenosis is crucially important. Current experience in
ercutaneous aortic valve replacement is limited to a few groups, and the search for
n optimal technique continues. We report our experience with retrograde endovas-
ular bioprosthesis implantation with brief cardiopulmonary bypass support in
igh-risk older patients.
ethods: The CoreValve pericardial bioprosthesis (CoreValve, Inc, Paris, France)
s sutured on a nitinol frame and delivered in a 21F catheter. All procedures were
erformed under femoro–femoral cardiopulmonary bypass support consisting of an
ortic balloon valvuloplasty followed by prosthesis deployment within the aortic
nnulus under fluoroscopy. Ten high-risk surgical patients underwent percutaneous
alve replacement.
esults: Immediate improvement in aortic valve function was observed in all
atients. The aortic valve area increased from 0.57  0.19 to 1.2  0.35 cm2 (P 
00001), the mean transaortic valve gradient decreased from 51  19 to 11  3 mm
g (P  .001). The 30-day mortality was 20%: one patient died 5 days after the
rocedure of a massive ischemic stroke and 1 patient died at 20 days of a
emorrhagic stroke. The median New York Heart Association functional class
mproved from III to II (P  .01).
onclusions: Aortic valve replacement with the CoreValve bioprosthesis can be
erformed with favorable early technical results in high-risk patients. However, the
orbidity and short-term mortality of such procedures remain significant.
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A
CDortic stenosis (AS) is one of the most common
forms of acquired valvular heart disease in
adults.1,2 Open chest aortic valve replacement
AVR) is the “gold standard,” improving survival and alle-
iating symptoms.2-4 Nevertheless, the surgical approach is
ssociated with substantial operative mortality rates in high-
isk patients. Consequently, almost one third of patients
ith severe AS are not offered surgery owing to a combi-
ation of reasons such as advanced age, impaired left ven-
ricular function, redo procedure, or multiple comorbidi-
ies.5 The prevalence of AS increases with age,2 and as
ongevity within the general population is increasing, the
roportion of AS patients with contraindications for surgery
s also expected to increase. Consequently, a less invasive
nd safer alternative to surgical aortic valve replacement for
hese patients is being increasingly recognized.
Balloon aortic valvuloplasty, originally described in the
980s,6 was the first alternative to surgical therapy. How-
ver, despite high rates of procedural success, restenosis led
o disappointing results in the longer term in adult patients
nd has been abandoned.7 Recent success with percutaneous
ulmonary valve implantation8 supports the possibility of
ercutaneous aortic valve replacement (PAVR). So far,
arly experience with this technique in humans is limited to
 few devices.9-11
The optimal approach for PAVR continues to be inves-
igated and several questions require clarification: method
Abbreviations and Acronyms
AS  aortic stenosis
AVR  aortic valve replacement
PAVR percutaneous aortic valve replacement
TEE  transesophageal echocardiographyThe Journal of Thoracicf approach (transaortic vs transapical), delivery catheter
ize, and circulatory support (cardiopulmonary bypass, tem-
orary left ventricular assistance, or rapid ventricular
acing).
We report our early experience with a new endovascular
echnology allowing retrograde implantation with brief pe-
ipheral cardiopulmonary bypass support.
atients and Methods
igh-risk patients with severe symptomatic AS were referred for a
ercutaneous procedure because of a high or prohibitive risk with
onventional surgery. The procedures were approved by the Ther-
peutic Products Directorate, Department of Health and Welfare,
ttawa, Canada, for compassionate clinical use in patients unsuit-
ble for surgery. Informed written consent was obtained.
We reviewed our initial 9-month experience from December
005 to August 2006. Patients underwent transthoracic echocardi-
graphy, iliofemoral contrast angiography, and coronary angiog-
aphy. Clinical evaluation and echocardiograms (VIVID7; GE
ealthcare, Milwaukee, Wis) were obtained before the procedure,
ithin 24 hours of the procedure, at day 10, and at 1 month after
he procedure.
rosthetic Valve System
he CoreValve aortic valve prosthesis (CoreValve, Inc, Paris,
rance) consists of a single-size bioprosthetic valve made of
orcine pericardial tissue, which is mounted and sutured in a
elf-expanding hourglass-shaped 55-mm length nitinol frame (Fig-
re 1, A). The lower part of the frame has a high radial force to
vercome valvular calcification and prevent recoil, and it serves to
nchor the prosthesis in the annulus. The mid part of the frame is
onstrained to avoid coronary ostia and carries the valve leaflets,
hereas the upper part expands in the proximal ascending aorta to
nsure stability and central alignment of the prosthesis. The actual
alve inner diameter is 22 mm. At the time of the procedure, the
itinol valve is chilled in cold saline and retracted into the 21F
elivery catheter by a compression and loading system.
Figure 1. CoreValve percutaneous aortic
prosthesis (A). Perioperative x-ray imag-
ing demonstrating 23-mm balloon dilata-
tion of the stenotic aortic valve (B). Ret-
rograde delivery catheter advancement
toward the aortic arch and deployment of
the prosthesis (C–E). A perioperative an-
giogram demonstrated excellent position
and function of the bioprosthesis. The left
and right coronary ostia are patent. There
is no evidence of intraprosthetic or
periprosthetic insufficiency (F).and Cardiovascular Surgery ● Volume 134, Number 5 1151
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A
CDrocedure
he procedures were conducted in a sterile cardiologic interven-
ional suite (Allura X per FD 10; Philips, Eindhoven, The Neth-
rlands) in accordance with the World Health Organization’s rec-
mmendations on air handling in surgical suites. The infrainguinal
liofemoral arterial junction was surgically exposed bilaterally.
hrough either right radial or brachial artery access, angiography
f the ascending aorta was performed via a right anterior oblique
iew. After this, a straight Terumo Glidewire (Terumo Medical
orp, Somerset, NJ) was advanced through the iliofemoral arteri-
tomy and directed across the aortic valve with an Amplatz AL1
r AL2 diagnostic catheter (Cordis Corp, Miami, Fla). This wire
as then exchanged for a 0.035-inch Amplatz Extra Stiff (Boston
cientific, Natick, Mass) guidewire to maintain a secure wire
osition within the left ventricle. The patient was heparinized (3
g/kg), and then venous (21F-23F) and arterial femoral canulas
17F or 19F) were inserted, permitting femoro–femoral cardiopul-
onary bypass. Transesophageal echocardiography (TEE) and
uoroscopy were used to optimize venous cannula positioning in
he right atrium during cardiopulmonary bypass. Valvuloplasty
ith a 23F balloon catheter (Numed, Hopkinton, NY) was first
erformed to optimize the valve area (Figure 1, B). After this, a
elivery catheter was advanced under fluoroscopic guidance (Fig-
re 1, C and D). The prosthesis was positioned with its distal third
djacent to the calcified native leaflets under fluoroscopy. The
rosthesis was deployed by careful retraction of the delivery
heath (Figure 1, E and F). Angiograms and TEE were systemat-
cally performed to verify the position and competent function of
he prosthesis, as well as the patency of the coronary ostia. If
ignificant periprosthetic leaks occurred immediately after PAVR,
ntraprosthetic balloon dilatation was performed to achieve an
ptimal seal with the aortic annulus. Cardiopumonary bypass was
hen progressively weaned, followed by removal of the sheath and
annulas and reversal of heparin.
reoperative and Postoperative Care
ll patients received either vancomycin or cefazolin intravenously
1 g) immediately before the procedure. Antibiotic prophylaxis
as systematicaly continued for 48 hours. Combination therapy
ith aspirin (325 mg) and clopidogrel (300 mg loading dose
ollowed by 75 mg daily maintenance dose) was started preoper-
tively and given after the procedure for 3 months. Aspirin (80 mg
aily) monotherapy was then continued indefinitely. Low-dose
ubcutaneous heparin (5000 IU twice daily) was administered for
hromboprophylaxis until patients were ambulatory.
tatistical Analyses
ontinuous normally distributed variables are expressed as mean 
D and analyzed by the paired Student t tests or analysis of
ariance. Continuous non-normally distributed data are expressed
s median (interquartile range) and analyzed with a Wilcoxon or
ruskal–Wallis test Categorical data were analyzed by a Pearson
2 test. All statistical analyses were undertaken with StataCorp
ersion 7 software (StataCorp, College Station, Tex). Adjustments
ere not made for multiple testing. l
152 The Journal of Thoracic and Cardiovascular Surgery ● Novesults
atients
AVR with full cardiopulmonary bypass was performed in
0 patients with severe symptomatic AS between December
005 and August 2006. Patients’ pre-procedural character-
stics are shown in Table 1. Three patients were in New
ork Heart Association class IV and the others were in class
II (n  7). Nine patients were 80 years old or more. All
atients had been deemed by at least two cardiothoracic
urgeons to be at prohibitively high surgical risk for con-
entional open chest AVR. The predicted mortality rates if
onventional procedures were performed were 22.9% 
5.3% and 32% (21%–40%), respectively, according to the
arsonnet and logistic EuroSCORE preoperative risk esti-
ation scores. Specific contraindications for surgery are
ABLE 1. Preoperative characteristics of 10 patients
ean age (y) 81.3 (range 64–85)
ale gender, n (%) 5 (50)
oronary artery disease, n (%) 6 (60)
V systolic dysfunction (EF  30%), n (%) 4 (40)
ean (SD) EF (%) 48 18
rior or current smoking, n (%) 2 (20)
OPD,* n (%) 6 (60)
YHA functional class, median (range) 3 (3, 4)
iabetes mellitus, n (%) 3 (30)
ypertension, n (%) 7 (70)
enal insufficiency,† n (%) 7 (70)
eripheral vascular disease,‡ n (%) 6 (60)
arotid artery disease, n (%) 5 (50)
rior cardiac surgery, n (%) types:
MVR 1 (10)
CABG 3 (30)
hronic atrial fibrillation, n (%) 4 (40)
ermanent pacemaker, n (%) 3 (30)
ulmonary hypertension,§ n (%) 8 (80)
ASP 30 mmHg 60 mmHg 3 (30)
ASP 60 90 mmHg 5 (30)
reoperative aspirin use, median (range) 4 (4-4)
arsonnet score 31.6 7.3
arsonnet predicted mortality 22.9 15.3
ogistic EuroSCORE, median (interquartile
range)
32% (21%–40%)
ogistic EuroSCORE  20% 8 (80%)
V, Left ventricular; EF, ejection fraction; SD, standard deviation; COPD,
hronic obstructive pulmonary disease; NYHA, New York Heart Associa-
ion; MVR, mitral valve replacement; CABG, coronary artery bypass graft-
ng; PASP, pulmonary artery systolic pressure. *Chronic obstructive pul-
onary disease  a history of respiratory problems associated with
aintentance inhaled bronchodilator therapy and forced expiratory volume
n 1 second 50%. †Renal insufficiency serum creatinine concentration
clearance of creatinine  40 mL/min). ‡Peripheral vascular disease is
efined by a history of symptomatic claudication or angiographic evidence
f peripheral vascular disease. §Pulmonary hypertension  pulmonary
rtery systolic pressure  25 mm Hg.isted in Table 2.
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A
CDrocedures
alvuloplasty, delivery catheter positioning, and biopros-
hetic valve deployment were successful in all patients. No
atient died during the procedure and no patient required
onversion to a conventional open chest procedure (Table
). Mean procedure time was 3.2  0.9 hours.
Positioning of the venous cannula in the right atrium and
he efficiency of the venous return were assessed with TEE
nd fluoroscopy. Vacuum-assisted venous return was used
f necessary (20–40 mm Hg). Median cardiopulmonary
ypass time was 28 minutes (range: 19–83 minutes). One
atient underwent a combined procedure with angioplasty
nd stent implantation for a tight stenosis of the left anterior
escending artery and AVR. Two patients required percu-
aneous angioplasty of the common iliac artery to allow
rogression of the sheath. In one 85-year-old patient (patient
), after percutaneous angioplasty and successful placement
f the prosthesis, periprocedural TEE identified a large
therosclerotic plaque in the left ventricular outflow tract. The
ebris was retrieved with an endovascular bioptome and ex
ivo analysis confirmed the tissue to be vascular, most likely
liac artery tissue displaced by delivery catheter advancement.
he procedure was complicated by a hemopericardium (owing
o the bioptome manipulation) that required emergency peri-
ardiocentesis. The patient subsequently experienced hemor-
hagic shock in the early postoperative period, and surgical
xploration of the abdomen identified hepatic trauma and in-
raperitoneal hemorrhage.
ostoperative Course
ean mechanical ventilation time was 7.8  4.7 hours. All
atients had mild transient elevation of creatine kinase MB
nd troponin T as indicated in Table 3. The operative
30-day) mortality was 20% and hospital mortality was 30%
ABLE 2. Specific contraindications for surgery
atient Gender Age Patient comorbidity
1 F 64 Pulmonary fibrosis; FEV1  0.4
2 F 85 Severe COPD*
3 M 80 PVD; prior CABG
4 F 82 Connective tissue disease
5 F 81 Severe COPD; cardiac cachexia;
kyphoscoliosis
6 M 84 Severe heart failure; cachexia
7 M 85 PVD; severe COPD
8 M 83 Severe COPD
9 M 85 Prior CABG, renal failure
10 F 84 Prior MVR; severe COPD*
EV1, Forced expiratory volume in 1 second; COPD, chronic obstructive
ulmonary disease; PVD, peripheral vascular disease; CABG, coronary
rtery bypass grafting; MVR, mitral valve replacement. *FEV1  50%
rejected in surgery by 2 surgeons).including operative mortality). Postoperative complica- h
The Journal of Thoracicions are shown in Table 3. Patient 7 died on the fifth
ostoperative day after a massive hemispheric ischemic
troke. One patient had a postoperative ophthalmoplegia
elated to an embolic event. Three other patients had tran-
ient confusion without computed tomographic evidence of
erebral embolization. Two patients required pacemaker
mplantation because of persistent atrioventricular block.
wo patients had transient nonsustained atrial fibrillation.
ascular access complications were encountered in 5 pa-
ients: 1 had a hematoma, 2 had lymphoceles, and 2 required
emoral arterial reconstructions (patch angioplasty). Femo-
al wound infection was encountered in 1 patient with
ilateral lymphoceles. Two patients required reoperation, 1
patient 7) because of intra-abdominal bleeding related to
ericardial (and inadvertent hepatic) puncture (patient 7)
nd another for an infected inguinal lymphocele. The mean
ntensive care unit stay was 4.6  2.2 days and the mean
ABLE 3. Procedures and postoperative course
rocedural outcomes
Successful valvuloplasty, n (%) 10 (100)
Successful prosthesis implantation, n (%) 10 (100)
Combined procedure (coronary angioplasty 
AVR, n (%)
1 (10)
Perioperative peripheral artery angioplasty, n (%) 2 (20)
ostprocedural outcomes
Blood transfusion  2 units, n (%) 6 (60)
Mean (SD) mechanical ventilation time, h 7.8 4.7
Mean (SD) ICU stay, d 4.6 2.2
Mean (SD) hospital stay, d 15 12
Day 0 11.4  4.9
Day 1 26.5  27.9
Day 2 14.1  11.8
Myocardial infarction (CK MB  100 mg/L or
new Q wave, n (%)
0
Mean (SD) troponin T concentration* (g/L)
Day 0 0.54  0.7
Day 1 0.5 0.4
Day 2 0.96  0.92
Death  30 d 2 (20)
Stroke, n (%) 2 (20)
New permanent pacemaker implantation, n (%) 3 (30)
cute renal failure requiring temporary renal
replacement therapy, n (%)
1 (10)
Nonsustained atrial fibrillation, n (%) 2 (20)
Major bleeding, n (%) 2 (20)
Vascular access site complication,† n (%) 3 (30)
onfusion, n (%) 3 (30)
Respiratory tract infection, n (%) 1 (10)
VR, Aortic valve replacement; SD, standard deviation; ICU, intensive care
nit; CK MB, creatine kinase MB. *Cardiac biomarker reference ranges:
reatinine kinase MB mass 0-5 mg/L; troponin T 0-0.03 /L. †Hematoma,
 2; lymphorrhea, n  1; infection, n  1 (1 patient had a hematoma and
wound infection).ospital stay was 15  12 days.
and Cardiovascular Surgery ● Volume 134, Number 5 1153
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A
CDerioperative Prosthesis Evaluation
he prosthesis was assessed at the end of each procedure by
tilizing TEE and angiography. Immediate improvement in
ortic valve function was observed in all patients. The aortic
alve area increased from 0.57  0.19 to 1.2  0.35 cm2 (P
 .00001) (Figure 2, A) and the mean transaortic valve
radient decreased from 51  19 to 11  3 mm Hg (P 
001) (Figure 2, B). Five patients had mild intraprosthetic
nsufficiency (1) and 8 patients had a mild-to-moderate
eriprosthetic leak (grade 1/4 [n  7] or 2/4 [n  1];
igure 2, C). Perivalvular leak remained stable over the
rst month.
ollow-up (1 Month)
ne patient had an intracerebral hemorrhage on day 20 and
ied. New York Heart Association class improved by at
east one point in all surviving patients (Figure 2, D). No
atient had any hemolysis or evidence of endocarditis, and
o patient required any reintervention for valve dysfunction
r any hospital readmission. The 3-month mortality was
0% and our first patient remains well more than 16 months
fter the procedure. The 3-month mortality was 30% and
ur first patient remains well more than 16 months after the
Figure 2. Improvements in the aortic valve (AV) area (A
Aortic valve regurgitation remained mild (< grade 2,
follow-up (C). Improvement in New York Heart Associa
data for 1 patient. PAVR, Percutaneous aortic valve rerocedure. v
154 The Journal of Thoracic and Cardiovascular Surgery ● Novostmortem Prosthesis Assessment
n autopsy was performed in the patient who died on day 5
patient 7). Postmortem assessment confirmed good pros-
hetic valve position and function and found no evidence of
ny device-related complication. The coronary ostia were
atent.
iscussion
e report the initial Montreal Heart Institute experience
ith endovascular implantation of a self-expanding aortic
alve prosthesis. We have confirmed that implantation of
he prosthesis is feasible, leading to an immediate increase
n the valve surface area and a decrease in the transaortic
ean gradient. Although every patient had a minor degree of
ortic regurgitation, it remained mild to moderate ( grade 2
nd  grade 1 in most) in all cases. Short-term follow-up in
urvivors confirmed that these initial results were maintained.
one of the patients had problems as a result of unstable
oronary artery disease during follow-up. These results con-
rm the potential for safe and effective PAVR.
Our approach differs from the Cribier–Edwards Life-
ciences system in several important ways. By contrast with
his latter balloon-expandable stent prosthesis,12,13 the de-
mean transaortic gradient after endovascular AVR (B).
grade 1 in most) immediately after AVR and during
NYHA) functional class (D). Each curve represents the
ment; AI, aortic insufficiency; SD, standard deviation.) and
and <
tion (
placeice used in this series is a self-expanding aortic valve
ember 2007
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A
CDrosthesis designed for retrograde implantation via the ar-
erial iliofemoral arteries. Whereas animal studies have
hown that the balloon-expandable prosthesis requires exact
evice positioning to avoid device embolization,14 the
onger profile and self-expandable properties of nitinol
ould enhance the stability once deployed.15 Even though
itinol devices could be susceptible to fracture with time,
he same self-expandable technology is commonly used in
horacic aortic stent grafts and has shown good midterm
esults.16 After device deployment, intraprosthetic balloon
xpansion can also be performed to minimize periprosthetic
egurgitation but is seldom required.
Mild-to-severe paravalvular aortic regurgitation has been
bserved in most patients who have undergone percutane-
us implantation of the balloon-expandable valve prosthe-
is.17 One possible advantage of a self-expanding pros-
hesis is the potential for continued expansion over time,
hich may in turn reduce paravalvular leaks after
mplantation.15
One theoretical advantage of the antegrade approach is a
ower risk of atheroma embolism during delivery catheter
dvancement through an atheromatous aorta. Nevertheless,
he need for transseptal puncture, unavoidable traction on
he anterior mitral valve leaflet inducing potentially severe
itral regurgitation, and hemodynamic instability constitute
he main drawbacks of this approach.15,18 Emerging ad-
ances in percutaneous procedures include reduced delivery
atheter size (ie, 18F delivery system) and alternative ap-
roaches (retrograde subclavian or transapical approaches),
hich may reduce the risk of implantation failure in
atients with severe peripheral vascular disease. These
ew approaches may limit the risk of femoral access site
omplication.
The relatively brief cardiopulmonary bypass times in this
eries were sufficient to unload the left heart cavities, ensure
emodynamic stability, and secure the release of the pros-
hesis in the correct position. Circulatory support may rep-
esents a safer alternative to brief rapid cardiac pacing
200–220 beats/min) in patients with severe AS and left
entricular hypertrophy inasmuch as low cardiac output
ay lead to myocardial ischemia and subsequent hemody-
amic instability. Therefore, this was chosen as our method
f choice for the beginning of our experience with endo-
ascular replacement of the aortic valve.
The mortality rate observed in our series was similar to
hat which was predicted using the Parsonnet and Euro-
COREs (20% vs 23%–24%). Three patients were not
andidates for surgery and the others were deemed to be
ery poor candidates for conventional surgery. Two had
evere lung disease prohibiting any kind of thoracic explora-
ion and 1 had severe kyphoscoliosis making a classic opera-
ive approach impossible. Other scoring systems may help to
The Journal of Thoracicbtain a better stratification and uniform preoperative risk
eporting for endovascular aortic replacement in the future.19
The high 1-month mortality was associated with neuro-
ogic complications in 2 patients. These complications
ould possibly be prevented by alternate vascular access in
atients with peripheral vascular disease. However, the
emorrhagic stroke at 20 days can be related to the antico-
gulation regimen; this was adjusted for the following pa-
ients. These comorbidities and the complex postprocedural
upport needed for these patients before discharge are re-
ected by a prolonged hospital stay. Long-term follow-up
f our patients is ongoing. Immediate improvements of the
ortic valve surface area were observed in all patients,
evice-related complications did not occur, and New York
eart Association functional class improved in all patients,
espite their comorbidities.
As reported in aortic endovascular interventions, the
ain risks for this type of procedure are also embolic stroke
nd technical problems related to peripheral vascular dis-
ase.20 The significant length of hospital stay in our patients
ndicates their complex postprocedural supportive needs
efore discharge.
onclusions
ndovascular AVR with a self-expandable bioprosthesis
an be performed with favorable immediate results in a
ohort of older and high-risk surgical patients. However, the
hort-term mortality of these patients remains high, most
ikely due to significant comorbidity. Notably, neurovascu-
ar complications are an important postprocedural compli-
ation. Prospective studies involving larger numbers of
igh-risk surgical patients are required to evaluate the po-
ential utility of this emerging and promising technology.
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